{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancer&page=13&q=HNSCC", "query": { "q": "HNSCC", "condition": "Head and Neck Cancer", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1257, "total_pages": 126, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancer&page=14&q=HNSCC&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancer&page=12&q=HNSCC&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T21:02:10.367Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03057613", "title": "The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "IMRT 60-66Gy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-05-10", "completion_date": "2020-09-09", "has_results": true, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03057613" }, { "nct_id": "NCT00006360", "title": "Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Radiation Toxicity" ], "interventions": [ { "name": "radioprotection", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 15, "location_summary": "Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006360" }, { "nct_id": "NCT02258659", "title": "Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papilloma Virus Infection", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2014-09-22", "completion_date": "2024-09-06", "has_results": true, "last_update_posted_date": "2024-09-24", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02258659" }, { "nct_id": "NCT04595981", "title": "Chemo-embolization for Head and Neck Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SCCHN", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2027-05", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04595981" }, { "nct_id": "NCT03729596", "title": "MGC018 With or Without MGA012 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer", "Melanoma", "Advanced Solid Tumor, Adult", "Metastatic Castrate Resistant Prostate Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2018-11-21", "completion_date": "2023-03-18", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 9, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03729596" }, { "nct_id": "NCT00899769", "title": "Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "proteomic profiling", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "liquid chromatography", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 100, "start_date": "2005-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899769" }, { "nct_id": "NCT03625323", "title": "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "HNSCC" ], "interventions": [ { "name": "eftilagimod alpha", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immutep S.A.S.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2019-02-21", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 1, "location_summary": "Huston, Texas", "locations": [ { "city": "Huston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03625323" }, { "nct_id": "NCT04034225", "title": "Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "SNS-301", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sensei Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2019-11-11", "completion_date": "2021-06-28", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 10, "location_summary": "San Francisco, California • Newark, Delaware • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04034225" }, { "nct_id": "NCT02565758", "title": "ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Undifferentiated Pleomorphic Sarcoma", "Squamous Cell Carcinoma of the Head and Neck", "Carcinoma of the Breast" ], "interventions": [ { "name": "ABBV-085", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2015-09-18", "completion_date": "2019-03-25", "has_results": false, "last_update_posted_date": "2019-04-05", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02565758" }, { "nct_id": "NCT02128906", "title": "Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "IMRT", "type": "RADIATION" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Christopher Wilke", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2013-12-23", "completion_date": "2031-12-16", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-19T21:02:10.367Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02128906" } ] }